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Abstract
Background: Triiodothyronine regulates proliferation acting as stimulator or inhibitor. E2F4 and
E2F5 in complexes with pocket proteins p107 or p130 stop cells in G1, repressing transcription of
genes important for cell cycle progression. p107 and p130 inhibits activity of cyclin/cdk2 complexes.
Expression of all those proteins could be regulated by triiodothyronine. In clear cell renal cell
carcinoma many disturbances in T3 signaling pathway was described, in that type of cancer also
expression of some key G1 to S phase progression regulators was shown.
Methods: We investigated role of T3 and its receptors in regulation of proliferation of HK2, Caki-
2, Caki-1 cell lines (cell counting, cytometric analysis of DNA content) and expression of thyroid
hormone receptors, E2F4, E2F5, p107 and p130 (western blot and semi-quantitative real time
PCR). Statistical analysis was performed using one-way ANOVA.
Results and Conclusion: We show that T3 inhibits proliferation of HK2, and stimulates it in Caki
lines. Those differences are result of disturbed expression of TR causing improper regulation of
E2F4, E2F5, p107 and p130 in cancer cells.
Background
Thyroid hormone – triiodothyronine – regulates cells dif-
ferentiation, proliferation and programmed death. Triio-
dothyronine acts both as an activator and inhibitor of
cells proliferation [1]. Thyroid hormones act mainly by
their nuclear receptors, which are ligand dependent tran-
scription factors. Depending on type of TRE (thyroid hor-
mone response elements) they could activate or inactivate
transcription of TH regulated genes [2]. There are evidence
that T3/TR negatively regulates E2F1 transcription [3].
However, it has been also reported TRβ receptors inhibits
cells proliferation independently on triiodothyronine
[4,5].
E2F4 and E2F5 belongs to E2F transcription factors fam-
ily. Those two E2Fs do not have nuclear localization signal
and their binding to promoters depends on interactions
with p107 and p130 [6]. p107 and p130 belong to the
family of retinoblastoma suppressor proteins [7]. E2F4 or
E2F5 in complexes with p107 or p130 when connected,
take part in formation of CERC (cyclin E repressor com-
plex). In G1 phase CERC binds to CCNE1  promoter
repressing transcription, and inhibiting proliferation.
Phosphorylation of p107 and p130 by kinases results in
CERC dissociation and activation CCNE1  transcription
and cell cycle progression [8]. Other cell cycle regulatory
genes are regulated in the same way. p107 and p130 in
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addition to creating CERC, could inhibit proliferation
also by inhibiting the activity of cyclin E/cdk2 and
cyclinA/cdk2 complexes [9].
At least 3% of human cancers are kidney cancers. Clear
cell renal cell carcinoma (ccRCC) is the most common
subtype of renal cancer, representing 75–82% of primary
malignancies of the kidney [10,11]. T3 signaling pathway
is disturbed in that type of cancer – patients with ccRCC
suffer from LTS (low triiodothyronine syndrome) [12],
expression of type I deiodinase mRNA and its activity are
lowered in ccRCC [13], expression of TRα1 and TRβ1 is
disturbed [14,15], lowered biding of TR to DNA [16], low-
ered biding of T3 to TR [15,17] and mutations of TR [16].
Those disturbances frequently result in improper G1/S
phase progression [18]. Elevated levels of E2F1 and cyclin
E1 and its LMW were described in ccRCC [16,17,19].
Basing on those facts we decided to investigate influence
of triiodothyronine on cell proliferation and expression of
TRs, E2F4, E2F5, p107 and p130. That type of triiodothy-
ronine action was never examined in kidney and ccRCC
cells, and the results could shed the light, how the distur-
bances in T3 signaling pathway affect cell proliferation in
ccRCC.
Methods
Cell culture, maintenance, synchronization, and flow 
cytometric assay
HK2 – human proximal tubules cell line, Caki-2 – human
ccRCC cell line, Caki-1 human ccRCC skin metastasis.
Cells were cultured in 75 cm2, 25 cm2 cell culture flasks
and 6 or 12 well plates (Corning-Star) in (HK2) KSFM
medium (Gibco) or (Caki-2, CAki-1) Mc'Coy 5A Medium
(Gibco) supplemented with 10% Charcoal-Dextran
treated FBS (Hyclone), antibiotics (Penicillin-Streptomy-
cin solution Sigma) and with or without 100 nM triio-
dothyronine. Cells were synchronized by 24 h serum
depletion. For growth curves and flow cytometry cells
were harvested by trypsynization and counted in Malassez
chamber every two hours. For expression assays, western
blot and flow cytometry cells were harvested by trypsyni-
zation at three points of cell cycle G1, G1/S and S (at 4th,
8th and 12th hour after synchronization for HK2; at 18th,
22nd and 26th for Caki-2; at 12th, 16th and 20th for Caki-
1). For flow cytometric analysis synchronized cells were
harvested and fixed in 70% ethanol. DNA content was
established by method described by Fan [20] on FACSCal-
ibur (Becton Dickinson) briefly, cells were washed with
PBS, treated with RNase (Sigma; 500 units/ml) at 37°C
for 15 min, and stained with propidium iodide (Sigma; 50
μg/ml).
Isolation of cell lysates
Cells were lysed for 30 minutes in 100 μl ice cold buffer
containing 50 mM Tris (pH7,4), 150 mM NaCl, 0,5 %
NP40, 50 mM NaF, 1 mM Na3VO4 1 mM DTT, 1 mM
PMSF, protease inhibitor cocktail (SIGMA) and 10 μg/ml
trypsin inhibitor. Then lysates were centrifuged at 18000
g for 5 min. Supernatants divided into 30 μl aliquots and
stored at -70°C. The amount of protein in supernatant
was established by Bradford method.
Isolation of nuclear protein
The buffers used for isolation were as described by Kane
[21]. All buffers were supplemented with protease inhibi-
tor cocktail (SIGMA) and PMSF (0.5 mM). Cell were sus-
pended in 1 ml of ice-cold STM buffer (20 mM Tris-HCl,
0.25 M sucrose, 1.1 mM MgCl2; pH 7.85) and centrifuged
at 1000 g for 10 min at 4°C. The resulting pellet was
washed twice in 1 ml of STM buffer with 0.5% Triton X-
100, followed by centrifugation under the same condi-
tions. The final pellet was resuspended in 0.1 ml KSTM +
20% glycerol buffer (20 mM Tris, 0.25 M sucrose, 1.1 mM
MgCl2, 0.4 mM KCl, 20% glycerol; pH 7.85), sonicated
and incubated on ice for 30 minutes with vortexing every
5 min to extract the soluble nuclear proteins. After solubi-
lization, the suspension was centrifuged at 12000 g for 15
min at 4°C. The amount of protein in supernatant was
established by Bradford method. The protein extracts were
divided into 30 μl aliquots and stored at -70°C.
Western blot analysis
40 μg of cell lysate or nuclear protein extract was resolved
on 10% polyacrylamide gel (SDS-PAGE). After electro-
phoresis proteins were transferred onto nitrocellulose
membrane. Destained membranes were blocked over-
night at 4°C in 5% non-fat milk in TBS-T buffer (20 mM
Tris-HCl, 137 mM NaCl, 1 M HCl, 0.1% Tween-20; pH
7.6), washed twice in TBS-T for 10 min at RT, then incu-
bated for 2 h with mouse monoclonal anti-TR antibody (1
μg/ml TBS-T, Santa Cruz Biotechnology), mouse mono-
clonal anti-TRβ antibody (2 μg/ml TBS-T, NeoMarkers),
mouse monoclonal anti-p107 antibody (1 μg/ml TBS-T,
Santa Cruz Biotechnology) or mouse anti-actin antibody
(1:10000) for 1 h at RT, washed 3 times for 10 min in TBS-
T, incubated for 1 h at RT with horseradish peroxidase-
conjugated goat anti-mouse secondary antibody (1:2000
in TBS-T, Dako), and washed again as described above.
The proteins were detected by an enhanced-chemilumi-
nescence detection system (Supersignal West Pico chemi-
luminescent substrate, PIERCE) according to standard
procedures. The amount of the specific protein was esti-
mated from densitometry after normalization against β-
actin band.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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RNA isolation
Cells were suspended in 1,5 ml TRIZOL reagent (Invitro-
gen), incubated for 5 minutes at RT. Then 300 μl chloro-
form was added and mixed gently, incubated for 10
minutes and centrifuged for 15 minutes at 12000 g (4°C).
Upper aqueous phase was transferred to a new tube,
mixed with 0.5 ml isopropyl alcohol and incubated for 10
minutes at RT, centrifuged for 15 minutes at 12000 g
(4°C). RNA pellet was washed with 75% ethanol, dried
and resuspended in 50 μl DEPC-treated water.
Real-time PCR
The isolated RNA served as a substrate in reverse transcrip-
tion reaction and the obtained cDNA samples were used
in semi-quantitative real-time PCR analyzes. Reverse tran-
scription was performed with RevertAidTM H Minus First
Strand cDNA Synthesis Kit (Fermentas) using oligo-dT
primer, according to manufacturer's protocol.
Real-time PCR reactions were performed with QuantiFast
SYBR Green PCR Kit (Qiagen) according to manufac-
turer's protocol. Primers are shown at table 1. Real-time
PCR conditions were as follows: initial denaturation:
95°C, 10 min., followed by 40 cycles: 95°C for 20 s, 59°C
for 30 s and 72°C for 60s; then melting curve analysis.
Expression levels were normalized to values obtained for
HPRT.
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis was
performed using one-way ANOVA, p < 0.05 was consid-
ered statistically significant.
Results and Discussion
Proliferation and cell cycle
HK2 cells divided slower than cells of cancerous cell lines
(Caki-2, Caki-1) (doubling time respectively 85 h, 35 h
and 30 h). Triiodothyronine inhibits proliferation of HK2
cells and stimulates it in Caki-2 and Caki-1 (Fig. 1A, 1B,
1C). T3 causes 10–20% drop of cell number in HK2, and
10–20% rise of cell number was observed in Caki-2 and
20–30% at Caki-1 (Figure 1D). After synchronization
from 85% (HK2) to 95%(Caki-2) cells was in G1 phase of
cell cycle. HK2 cells started entering S phase about 4 hours
after the end of synchronization. Maximal number of cells
(20%) in S phase was observed about 12 h after end of
synchronization. In the presence of T3 less HK2 cells
enters S phase (5–10%). Caki-2 cells enters S phase 14
hours after synchronization, maximal number of cells in
S phase (35%) was observed 28 hours after synchroniza-
tion. In the presence of triiodothyronine maximal
number of cells was observed from 24 to 28 hour after
synchronization, more cells was entering S phase (5%). In
Caki-1 cells S phase starts between 8th and 12th hour after
synchronization, maximal number of cells entering S
phase (40%) was observed 20 hours after synchroniza-
tion. In the presence of T3 maximal number of cells in S
phase rises to 50%.
It is known that proximal tubules proliferate slower than
ccRCC derived cells [22], therefore HK2, Caki-2 and Caki-
1 proved to be a proper cellular model for investigation of
differences in cell cycle between normal and cancerous
cells. Effects of triiodothyronine differs – there are evi-
dence for proproliferative effects of that hormone [23-25]
and antiproliferative action [26-28] in our experiments
triiodothyronine inhibits proliferation in HK2 cells and
stimulates it in cancerous cells. Results obtained from
flow cytometric analysis of DNA content suggest that
observed differences in cell cycle progression could be
effect of inappropriate G1 to S phase progression.
Expression of thyroid hormone nuclear receptors
Densitometric analysis of immunoblots revealed that
level of TR protein in HK2 lysates from cells cultured with-
out rises during cell cycle progression (G1:47632 ± 5230,
G1/S:61092 ± 7234, S:74248 ± 5698) (Figure 2B). In can-
cer cell lines Caki-2 and Caki-1 level of that proteins was
lower than in HK2 cells. In Caki-2 differently than in HK2,
TR protein level drops during progression of cell cycle
(G1:16380 ± 1224, G1/S:5480 ± 326, S:1600 ± 172).
TR proteins level was, also in the presence of triiodothyro-
nine, higher in HK2 than in cancerous cell lines. In HK2
TR proteins level drops at G1/S and raises at S (G1:70036
± 8921; G1/S:52124 ± 6213; S:63044 ± 5123), In Caki-2
decreases during cell cycle (G1:14409 ± 965; G1/S:10000
± 1234; S:3382 ± 298), and raises with cell cycle progres-
Table 1: Primers for SQ-RT-PCR
gene Primers sequences Product size
THRA GCCTTTAACCTGGATGACACG
GTGTTTGCGGTGGTTGACG
153 pz
THRB CCTGGGACAAACCGAAGCA
GATGAGATGTGGCGACGACT
140 pz
E2F4 GAGTGGTCCCATTGAGGTTC
GGCAGAGGTGGAGGTGTAG
129 pz
E2F5 TCAGGCACCTTCTGGTACAC
GGGCTTAGATGAACTCGACTC
145 pz
RBL1 GAGGTGGTGATCCGCTCAGA
TAGAGGAGACATTGGCATCAG
240 pz
RBL2 CAACAATGGGCAAACGGTAAC
GCCACTTGACCAGGGACTTG
207 pz
HPRT AGGACTGAACGTCTTGCTCG
GTTGGATTATACTGCCTGACC
350 pzThyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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Proliferation of cell lines Figure 1
Proliferation of cell lines. A) growth curve for HK2 cells cultured without or with 100 nM triiodothyronine B) growth 
curve for Caki-2 cells cultured without or with 100 nM triiodothyronine C) growth curve for Caki-1 cells cultured without or 
with 100 nM triiodothyronine D) differences in proliferation caused by 100 nM triiodothyronine.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
Page 5 of 13
(page number not for citation purposes)
sion (G1:5957 ± 435; G1/S:6627 ± 578; S:9548 ± 789) in
Caki-1 (Figure 2C).
Triiodothyronine causes raise of TR level at G1 in HK2
and decrease at G1/S and S. In Caki-2 influence of triio-
dothyronine was different – it caused drop at G1 and raise
at G1/S and S. In Caki-1 effects of triiodothyronine on the
level of TR protein was similar to that observed in Caki-2
cells (Figure 2D).
High level of TRs observed in HK2 cells confirms earlier
results obtained on tissue samples of ccRCC [14]. Low
level of TR in cancer cells suggests that effects of apo-
receptors will weaker in those cell lines than in proximal
tubules. As expected changes in level of TR proteins were
observed in HK2 cells – according to the literature level of
TRs rises during cell cycle progression [29]. Contrary, in
Caki-2 cells expression profile was improper – protein
level drops during progression.
Effects of T3 on TR level differs between HK2 and Caki-2
and Caki-1, suggesting improper action of TRs in those
cell lines. Disturbances of TR could be result of different
expression, but also improper action weak DNA [16] and
T3 binding [15,17] or possible mutations [16].
Densitometric analysis of immunoblots show that during
cell cycle progression (G1:248 ± 21; G1/S:334 ± 42; S:899
± 78) TRβ protein level raises in nuclear extracts HK2 from
cells cultured without triiodothyronine. In Caki-2 TRβ
level was higher than in HK2, and was raising at G1/S
(G1:1302 ± 154, G1/S:2800 ± 237) and decreasing at S. In
Level of main isoforms of thyroid hormone nuclear receptors (TRβ1 and TRα1) Figure 2
Level of main isoforms of thyroid hormone nuclear receptors (TRβ1 and TRα1). A) Representative immunoblots B) 
mean levels of TR in cells cultured without triiodothyronine C) mean levels of TR in cells cultured with 100 nM triiodothyro-
nine D) Changes of TR protein level caused by 100 nM triiodothyronine.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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Caki-1 raise of TR proteins level during cell cycle progres-
sion was also observed (G1:198 ± 13, G1/S:566 ± 56,
S:888 ± 78) (Figure 3B).
In the presence of triiodothyronine TRβ proteins level
drops at G1/S and rises at S (G1: 752 ± 120; G1/S:194 ±
14; S: 1700 ± 345) In Caki-2 TRβ level was similar to HK2
(730 ± 98, p > 0,05), and rises during cell cycle progres-
sion (G1/S:1100 ± 201, S:1500 ± 245). In Caki-1 at G1
and S TRβ level was lower than in HK2, and rises At G1/S
and diminishes at S (Figure 3C).
In HK2 cell line triiodothyronine causes rise of TRβ pro-
tein level at G1 and S, and drop at G1/S. In Caki-2 at G1,
effects of triiodothyronine was opposite to that observed
in HK2. In Caki-1 effect of triiodothyronine was weaker
than in HK2. In Caki-1 at S triiodothyronine acts as nega-
tive regulator of TRβ protein level (Figure 3D).
As opposed to the cell lysates level of TRβ in nuclear
extracts was higher in Caki-2 than in HK2. Similarly Puz-
ianowska-Kuźnicka at al [14] show raised level of TRβ1 in
30% of investigated ccRCC tissue samples. High level of
TRβ could be result of more efficient transport of TRs to
Level of thyroid hormone nuclear receptor TRβ Figure 3
Level of thyroid hormone nuclear receptor TRβ. A) Representative immunoblots B) mean levels of TRβ in cells cultured 
without triiodothyronine C) B) mean levels of TRβ in cells cultured with 100 nM triiodothyronine D) Changes of TRβ protein 
level caused by 100 nM triiodothyronine.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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nucleus in Caki-2 cells. In the presence of T3 there were no
differences between Caki-2 and HK2 in the level of TRβ,
which suggests that transport of TRs in Caki-2 is inde-
pendent of T3, its known that in normal cells transport of
TRs is hormone dependent [30]. Raising during cell cycle
level of TRβ suggest that effects of those receptors will be
higher in later phases of cell cycle. In cancerous cell lines
effects of T3 on TRβ are different than in HK2 cells. It sug-
gest that in cancer cells expression or protein degradation
is disturbed.
In HK2 cells cultured without triiodothyronine TRβ
mRNA level drops at G1/S and rises at S (G1:2,9 ± 0,24;
G1/S 0,3 ± 0,02; S:1,1 ± 0,05) (Figure 4A). In Caki-2 at G1
mRNA level was similar to observed in HK2 (2,8 ± 0,14),
remained unchanged at G1/S (2,8 ± 0,16, p > 0,05) and
decrease eight fold at S (0,33 ± 0,02). In Caki-1 level of
Expression of TRβ and TRα mRNA Figure 4
Expression of TRβ and TRα mRNA. A) Expression of TRβ in cells cultured without triiodothyronine B) Expression of TRβ 
in cells cultured with 100 nM triiodothyronine C) Changes in TRβ mRNA expression caused by 100 nM triiodothyronine D) 
Expression of TRα in cells cultured without triiodothyronine E) Expression of TRα in cells cultured with 100 nM triiodothyro-
nine F) Changes in TRα mRNA expression caused by 100 nM triiodothyronine.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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TRβ mRNA At G1 was lower than in (0,3 ± 0,0,2 p < 0,05).
In that line level of TRβ mRNA doubles at G1/S and drops
at S (0,32 ± 0,03 p > 0,05).
In the presence of T3 level of TRβ mRNA in HK2 drops at
G1/S and rises at S (Figure 4B). In Caki-2 level of TRβ
mRNA was lower at G1 than in HK2 (G1:0,3 ± 0,02),
declined at G1/S (0,1 ± 0,01) and raised at S (0,5 ± 0,02).
In Caki-1 level of TRβ mRNA was similar to observed in
HK2 (HK2:0,86 ± 0,04; Caki-1 0,90 ± 0,05 p > 0,05), but
level of that mRNA raises at G1/S to drop at S.
In HK2 cells triiodothyronine causes negative regulation
of TRβ expression at G1, positive at G1/S and has no effect
at S. (Figure 4C). In Caki-2 triiodothyronine regulates
expression negatively at G1 and G1/S and positively At S.
In Caki-1 triiodothyronine causes rise of mRNA level,
with diminishing effect over the cell cycle.
Triiodothyronine regulation of TRβ expression is different
in cancerous cell lines than in HK2 line, supporting the
hypothesis that TRs is disturbed in ccRCC.
In HK2 cells cultured without triiodothyronine level of
TRα mRNA rises during cell cycle progression (G1:0,7 ±
0,04; G1/S:1,2 ± 0,06; S:1,5 ± 0,08) (Figure 4D). In Caki-
2, differently than in HK2, level of TRα mRNA drops dur-
ing cell cycle progression (G1:1,0 ± 0,05; G1/S:0,5 ± 0,02;
S:0,2 ± 0,01). In Caki-1 the level of TRα mRNA was gener-
ally higher than in the other cell lines, with significant rise
at G1/S and drop at S (G1:1,6 ± 0,08; G1/S:4,6 ± 0,23;
S:2,3 ± 0,12).
In the presence of T3 level of TRα mRNA In HK2 drops at
G1/S and rises at S (G1:5,1 ± 0,26; G1/S:3,9 ± 0,20; S:20,0
± 1,00). In Caki-2 mRNA of this receptor was higher than
in HK2 and diminishes during cell cycle progres-
sion(G1:1,8 ± 0,09; G1/S:1,3 ± 0,07; S:0,2 ± 0,01). In
Caki-1 level of TRα mRNA rises at G1/S and drops at S
(Figure 4E).
In all cell lines triiodothyronine causes rise of TRα mRNA
level (Figure 4F).
In cells cultured without triiodothyronine expression pro-
file of TRα is different than in Caki-2 and Caki-1 lines,
suggesting that THRA expression is also disturbed in
ccRCC. In the presence of T3 in HK2 and Caki-2 expres-
sion pattern of TRα was opposite, once again suggesting
disturbances of TR regulation and expression in ccRCC.
Expression E2F4 and E2F5
In HK2 cells cultured without triiodothyronine, level of
E2F4 mRNA in G1/S was lower than In G1 and raised 10
folds in S (15,81 ± 0,80)(Figure 5A). In Caki-2 cells level
of E2F4 mRNA was decreasing during cell cycle progres-
sion (G1: 4,96 ± 0,25; G1/S3,64 ± 0,18; S: 1,87 ± 0,09)
and was statistically higher than in HK2 at G1 and G1/S
and lower at S. Level of E2F4 mRNA in Caki-1 cells was
increasing during cell cycle progression.
In the presence of triiodothyronine level of E2F4 mRNA
in HK2 cells remains unchanged at G1 and G1/S (27,1 ±
1,36; 26,5 ± 1,32 p > 0.05) and decreases at S (9,7 ± 0,48).
(Figure 5B). In cancerous line Caki-2 E2F4 mRNA level
was decreasing during cell cycle progression (G1: 21,1 ±
1,01 G1/S:6,7 ± 0,34 S:2,9 ± 0,14). Caki-1 at G1 (90,5 ±
4,60) E2F4 mRNA level was higher than in HK2 and Caki-
2, drops at G1/S (21,0 ± 1,05) and raises at S (38,1 ±
1,91).
In HK2 cells triiodothyronine causes raise of E2F4 level at
G1 and G1/S and drop at S. In Caki-2 T3 stimulates
expression of E2F4 mRNA, this effect is weakening with
cell cycle progression. In Caki-1 triiodothyronine effects at
G1 and S were stronger than in other cell lines.(Figure
5C).
Lower proliferation of HK2 cells could be attributed to the
higher level of E2F4. Lower level of E2F4 in Caki-2 and
Caki-1 lines is similar to that observed in breast [31] and
thyroid cancer [32]. In Caki-2 level of E2F4 mRNA
decreases during cell cycle progression it may result in
faster proliferation – E2F4 is known as an inhibitor of pro-
liferation. Lower level of E2F4 in the presence of T3 and
its drop during the cell cycle explain faster proliferation of
that cell line. Higher level in Caki-1 is hard to explain, but
it is known that in gastric cancers mutations of E2F4 were
observed [33]. For proper interpretation of those results
assessment of p107 and p130 levels is also important.
Effects of T3 on triiodothyronine expression were similar
in all cell lines, however slightly weaker in Caki-1.
In HK2 cells cultured without triiodothyronine E2F5
mRNA level raises during cell cycle progression (G1:0,87
± 0,04; G1/S:2,81 ± 0,014; S:6,93 ± 0,35). Caki-2 cells at
G1(9,68 ± 0,48) and S (5,43 ± 0,21) points has higher
level of E2F5 mRNA than in HK2. At those cells level of
that mRNA drops almost two-fold at G1/S. In Caki-1 E2F5
mRNA level was higher than in other cell lines (G1:11,05
± 0,55; G1/S:18,83 ± 0,94; S:9,25 ± 0,46). (Figure 5D).
In the presence of triiodothyronine in HK2 cells level of
E2F5 mRNA falls two-times at G1/S and rises at S (G1:5,1
± 0,25; G1/S:3,2 ± 0,16; S: 6,6 ± 0,33) (Figure 5E). Similar
changes were observed in Caki-2 cells, in Caki-1 cells, at
G1 E2F5 mRNA level was higher than in other cell lines,
with rise during G1/S and drop at S.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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Triiodothyronine causes stimulation of E2F5 expression
in HK2 and this effect was strongest at G1. In Caki-2 at G1
and G1/S triiodothyronine represses E2F5 mRNA expres-
sion, stimulation observed at S was weaker than in HK2.
Effects of triiodothyronine in Caki-1 were similar to those
observed in HK2 (Figure 5F).
According to the literature [34] higher level of E2F5
mRNA observed in cancer cell lines, should result in pro-
liferation inhibition, but such effect was never observed.
In breast cancer amplification of E2F5 gene was observed
[35]. Negative regulation of E2F5 expression by triio-
dothyronine in Caki-2 could be a reason of faster prolifer-
ation observed in that cell line.
Expression of p107 and p130
Densitometric analysis of immunoblots revealed that in
nuclear extracts from HK2 cells cultured without T3 level
of p107 was decreasing during cell cycle progression
(G1:1716 ± 200; G1/S:1525 ± 100; S:1254 ± 79) (Figure
6B). In Caki-2 level of p107 protein at G1 (1478 ± 100)
was lower than in HK2, and differently than in HK2 rises
Expression of E2F4 and E2F5 mRNA Figure 5
Expression of E2F4 and E2F5 mRNA. A) Expression of E2F4 in cells cultured without triiodothyronine B) Expression of 
E2F4 in cells cultured with 100 nM triiodothyronine C) Changes in E2F4 mRNA expression caused by 100 nM triiodothyronine 
D) Expression of E2F5 in cells cultured without triiodothyronine E) Expression of E2F5 in cells cultured with 100 nM triio-
dothyronine F) Changes in E2F5 mRNA expression caused by 100 nM triiodothyronine.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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at G1/S(2679 ± 187) and drops at S (1929 ± 138). In Caki-
1 p107 protein level at G1 (1545 ± 150) was similar to
Caki-1, at G1/S also rises (2208 ± 135) but raise was
weaker, at S(1871 ± 220 p107 protein level was similar to
that observed in Caki-2).
In the presence of triiodothyronine p107 protein level
doubles at G1/S and drops at S (G1:742 ± 100; G1/S:1626
± 170; S:1207 ± 97)(Figure 6C). In Caki-2 at G1 (1415 ±
150) p107 protein level was two fold higher than in HK2,
dropped at G1/S(344 ± 28) and raised at S (2195 ± 120).
In Caki-1 like in Caki-2, higher than in HK2 level of p107
protein was observed, changes in this protein level was
similar to Caki-2.
In HK2 cells triiodothyronine causes drop of p107 level at
G1 and has almost no effect at other parts of cell cycle(Fig-
ure 6D). In Caki-2 T3 has no effects at G1, but at G1/S
causes nine fold drop of p107 level. In Caki-1 at G1 (sim-
ilar to HK2) triiodothyronine causes drop of p107 protein
level and at G1/S (similar to Caki-2) causes fall of p107
protein level.
In Caki-2 and Caki-1 cell lines level of p107 was higher
than in HK2, similar to colon cancer [36]. In the presence
Level of p107 protein Figure 6
Level of p107 protein. A) Representative immunoblots B) mean levels of p107 in cells cultured without triiodothyronine C) 
mean levels of p107 in cells cultured with 100 nM triiodothyronine D) Changes of p107 protein level caused by 100 nM triio-
dothyronine.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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of T3 level of p107 in HK2 at G1/S is higher than in Caki-
2 and Caki-1 cell lines. Lowered protein level in cancerous
cell lines could be reason of faster proliferation. Triio-
dothyronine caused huge decrease of p107 protein level at
G12/S what is probably the reason of stimulatory effect of
T3 on Caki-2 and Caki-1 cells proliferation.
In HK2 cells cultured without triiodothyronine p107
mRNA was raising during cell cycle progression (G1:0,33
± 0,016; G1/S:0,42 ± 0,021; S:1,38 ± 0,069). In Caki-2
mRNA level also increases during cell cycle progression
(G1:0,86 ± 0,043 G1/S:0,99 ± 0,049 S:1,50 ± 0,075) p107
mRNA level was at G1 and G1/S higher than observed in
HK2. In Caki-1 level of p107 mRNA was lower than in
other lines, but also rises during cell cycle progression
(G1:0,07 ± 0,003 G1/S:0,21 ± 0,010 S:0,57 ± 0,028) (Fig-
ure 7A).
In the presence of triiodothyronine level of p107 mRNA
was rising during the cell cycle progression with peak at
Expression of p107 and p130 mRNA Figure 7
Expression of p107 and p130 mRNA. A) Expression of p107 in cells cultured without triiodothyronine B) Expression of 
p107 in cells cultured with 100 nM triiodothyronine C) Changes in p107 mRNA expression caused by 100 nM triiodothyronine 
D) Expression of p130 in cells cultured without triiodothyronine E) Expression of p130 in cells cultured with 100 nM triio-
dothyronine F) Changes in p130 mRNA expression caused by 100 nM triiodothyronine.Thyroid Research 2008, 1:5 http://www.thyroidresearchjournal.com/content/1/1/5
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G1/S and S (G1:1,09 ± 0,055; G1/S:1,34 ± 0,067; S:1,39 ±
0,068) (Figure 7B). In Caki-2 enormous drop of mRNA
p107 level was observed at G1/S (G1:1,72 ± 0,085; G1/
S:0,17 ± 0,08) and rise at S (0,86 ± 0,044). In Caki-1 level
of p107 mRNA was rising at G1/S and declining at S
(G1:0,60 ± 0,030; G1/S:1,03 ± 0,52; S:0,66 ± 0,033). Both
cancerous cell lines has lower level of p107 than HK2
(except G1 in Caki-2).
In HK2 triiodothyronine stimulates expression of p107
mRNA at G1 and G1/S, has no effect at S. In Caki-2 triio-
dothyronine causes rise of p107 mRNA level at G1, but at
G1/S an S T3 has negative effect on this mRNA expression.
In Caki-1 effects of T3 were similar to those observed in
HK2 (Figure 7C).
Higher level of p107 mRNA observed in the presence of
T3 in HK2 cells is probably reason of lower proliferation
due to repressing effects of CERC and inhibition of
cyclinE/cdk2 complexes. Reduced p107 mRNA level
observed in Caki-2 is reason of faster proliferation. Triio-
dothyronine causes enormous drop of p107 mRNA level
in Caki-2 cells which could stand for the proproliferative
effects of T3.
Level of p130 mRNA in HK2 cells cultured without T3 was
diminished at G1/S and doubled at S (G1:0,53 ± 0,026;
G1/S:0,44 ± 0,021; S:1,22 ± 0,059) (Figure 7D). In Caki-2
level of p130 mRNA at G1 was two fold higher than In
HK2, and rises during cell cycle progression (G1:0,32 ±
0,016; G1/S: 0,43 ± 0,021; S:0,77 ± 0,039). In Caki-1
mRNA p130 level at G1 was lower than in other cell lines
and was rising in cell cycle progression (G1:0,21 ± 0,010;
G1/S:0,90 ± 0,044; S:2,55 ± 0,120).
In the presence of T3 in HK2 cells level of p130 mRNA was
unchanged at G1 and G1/S (G1:1,61 ± 0,09; G1/S: 1,59 ±
0,07 p > 0,05) and decreases at S (S:0,89 ± 0, 041) (Figure
7E). In Caki-2 p130 mRNA level was lower than in HK2,
In G1/S level of this mRNA drops five fold at G1/S and
rises at S (G1:0,75 ± 0,03; G1/S: 0,16 ± 0,007; S:0,41 ±
0,003). In Caki-1 p130 mRNA level was higher than In
HK2 and Caki-2 cell lines, and rises at G1/S and decreases
at S (G1:2,77 ± 0,149; G1/S: 3,33 ± 0,166; S:2,90 ± 0,150).
In HK2 triiodothyronine stimulates expression of p130
mRNA at G1 and G1/S and causes repression at S. In Caki-
2 cells at G1 triiodothyronine stimulates expression, but
in G1/S causes drop of mRNA level, effect At S was strong-
est than in HK2. In Caki-1 stimulates expression of p130
at all investigated parts of cell cycle(Figure 7F).
Higher than in Caki-2 level of p130 observed in HK2
could be one of the reasons of slower proliferation of HK2
cells. Lowered level of p130 was also observed in ovarian
and endometrial cancer [37,38]. In the presence of T3
level of p130 was also higher in HK2 than in Caki-2, and
like with p107 huge decrease of mRNA at G1./S in Caki-2
line was observed. Those two facts are probably the reason
of slower HK2 and faster Caki-2 proliferation. The most
important effect of triiodothyronine seems to be down-
regulation of p130 mRNA observed at G1/S in Caki-2
cells. That is probably the reason of different effects of T3
observed in HK2 and Caki-2.
Conclusion
HK2 cell line proliferates slower than Caki-2 and Caki-1
lines. Those differences in cells cultured without triio-
dothyronine are result of lower E2F4 mRNA level in Caki-
2 and Caki-1 line, and lower p130 level in Caki-2 line. In
the presence of T3 faster proliferation of ccRCC cells is
result of lower E2F4 level which drops during cell progres-
sion, drop of p107 at G1/S, lower p130 and decrease of its
mRNA level with cell cycle progression.
Triiodothyronine has opposite effects on proliferation of
HK2 and Caki-2, Caki-1 cells. It inhibits proliferation of
proximal tubules cells and stimulates cancer cells prolifer-
ation. Those phenomena could be explained by Caki-2
negative regulation of E2F5, p107 and p130 expression
and decrease in p107 protein level, or limited to Caki-1
negative regulation of p130 expression.
The differences could be to some extent attributed to the
expression pattern of TR in different cell lines, however
this hypothesis needs more detailed investigation.
In our opinion the results could help to understand role
of T3 in ccRCC, and partially answer the question of
changes in regulation of proliferation of cancer cells
caused by disturbances in T3 signaling pathway.
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